Ierland - Engels - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/250 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 20mg equivalent to 125 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 125µg/25µg - active: fluticasone propionate 20mg equivalent to 125 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 40mg equivalent to 250 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 250µg/25µg - active: fluticasone propionate 40mg equivalent to 250 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 8mg equivalent to 50 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 50µg/25µg - active: fluticasone propionate 8mg equivalent to 50 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 100ug (micronised);  ;  ;  ; salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base;  ;  ;   - powder for inhalation - 100µg/50µg - active: fluticasone propionate 100ug (micronised)       salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base       excipient: lactose monohydrate - seretide is indicated for the regular treatment of asthma (reversible obstructive airways disease), where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of both long-acting beta-agonists and inhaled corticosteroids using separate therapy. patients who are not adequately controlled on current inhaled corticosteroid therapy. patients who are not adequately controlled on 'as needed' short-acting beta-agonistsm as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroids alone. seretide should not typically be used for the initial management of asthma, unless symptoms are severely uncontrolled, nor in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists. seretide should not be used in the treatment of acute asthmatic symptoms.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 250ug (micronised);  ;  ;  ; salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base;  ;  ;   - powder for inhalation - 250µg/50µg - active: fluticasone propionate 250ug (micronised)       salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base       excipient: lactose monohydrate - seretide is indicated for the regular treatment of asthma (reversible obstructive airways disease), where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of both long-acting beta-agonists and inhaled corticosteroids using separate therapy. patients who are not adequately controlled on current inhaled corticosteroid therapy. patients who are not adequately controlled on 'as needed' short-acting beta-agonistsm as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroids alone. seretide should not typically be used for the initial management of asthma, unless symptoms are severely uncontrolled, nor in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists. seretide should not be used in the treatment of acute asthmatic symptoms.

Nieuw-Zeeland - Engels - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 500ug (micronised);  ;  ;  ; salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base;  ;  ;   - powder for inhalation - 500µg/50µg - active: fluticasone propionate 500ug (micronised)       salmeterol xinafoate 72.5ug equivalent to 50 µg of salmeterol base       excipient: lactose monohydrate - seretide is indicated for the regular treatment of asthma (reversible obstructive airways disease), where use of a combination product (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of both long-acting beta-agonists and inhaled corticosteroids using separate therapy. patients who are not adequately controlled on current inhaled corticosteroid therapy. patients who are not adequately controlled on 'as needed' short-acting beta-agonistsm as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroids alone. seretide should not typically be used for the initial management of asthma, unless symptoms are severely uncontrolled, nor in patients whose asthma can be managed by occasional use of short-acting beta-2 agonists. seretide should not be used in the treatment of acute asthmatic symptoms.

Ierland - Engels - HPRA (Health Products Regulatory Authority)

rowex ltd - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25 microgram/125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ierland - Engels - HPRA (Health Products Regulatory Authority)

glaxosmithkline (ireland) limited - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/125 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ierland - Engels - HPRA (Health Products Regulatory Authority)

mcdermott laboratories ltd., t/a gerard laboratories - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25mcg /125 microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone